25 XP   0   0   10

BioXcel Therapeutics Inc
Buy, Hold or Sell?

Let's analyze BioXcel Therapeutics Inc together

I guess you are interested in BioXcel Therapeutics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of BioXcel Therapeutics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about BioXcel Therapeutics Inc

I send you an email if I find something interesting about BioXcel Therapeutics Inc.

Quick analysis of BioXcel Therapeutics Inc (30 sec.)










What can you expect buying and holding a share of BioXcel Therapeutics Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$-1.93
Expected worth in 1 year
$-5.27
How sure are you?
16.7%

+ What do you gain per year?

Total Gains per Share
$-3.34
Return On Investment
-309.3%

For what price can you sell your share?

Current Price per Share
$1.08
Expected price per share
$0 - $1.91
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

1. Valuation of BioXcel Therapeutics Inc (5 min.)




Live pricePrice per Share (EOD)

$1.08

Intrinsic Value Per Share

$-21.99 - $-25.05

Total Value Per Share

$-23.92 - $-26.97

2. Growth of BioXcel Therapeutics Inc (5 min.)




Is BioXcel Therapeutics Inc growing?

Current yearPrevious yearGrowGrow %
How rich?-$72.3m$105.2m-$146.1m-357.3%

How much money is BioXcel Therapeutics Inc making?

Current yearPrevious yearGrowGrow %
Making money-$38.2m-$48.1m$9.9m26.0%
Net Profit Margin-9,259.4%-20,436.3%--

How much money comes from the company's main activities?

3. Financial Health of BioXcel Therapeutics Inc (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  

3rd party ad coffee SUPPORTERis ad-free.

What can you expect buying and holding a share of BioXcel Therapeutics Inc? (5 min.)

Welcome investor! BioXcel Therapeutics Inc's management wants to use your money to grow the business. In return you get a share of BioXcel Therapeutics Inc.

What can you expect buying and holding a share of BioXcel Therapeutics Inc?

First you should know what it really means to hold a share of BioXcel Therapeutics Inc. And how you can make/lose money.

Speculation

The Price per Share of BioXcel Therapeutics Inc is $1.08. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of BioXcel Therapeutics Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in BioXcel Therapeutics Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $-1.93. Based on the TTM, the Book Value Change Per Share is $-0.84 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.94 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of BioXcel Therapeutics Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.71-66.1%-1.02-94.4%-1.25-115.4%-0.78-72.3%-0.55-51.0%
Usd Book Value Change Per Share-0.42-39.1%-0.84-77.3%-0.94-87.0%-0.14-12.9%-0.06-6.0%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.42-39.1%-0.84-77.3%-0.94-87.0%-0.14-12.9%-0.06-6.0%
Usd Price Per Share2.82-3.74-16.29-21.07-15.41-
Price to Earnings Ratio-0.99--0.97--3.23--8.82--8.67-
Price-to-Total Gains Ratio-6.68--5.25--18.52--28.69--34.70-
Price to Book Ratio-1.46-9.22-7.56-10.05-7.89-
Price-to-Total Gains Ratio-6.68--5.25--18.52--28.69--34.70-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share1.08
Number of shares925
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.84-0.14
Usd Total Gains Per Share-0.84-0.14
Gains per Quarter (925 shares)-772.47-129.06
Gains per Year (925 shares)-3,089.87-516.25
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-3090-31000-516-526
20-6180-61900-1032-1042
30-9270-92800-1549-1558
40-12359-123700-2065-2074
50-15449-154600-2581-2590
60-18539-185500-3097-3106
70-21629-216400-3614-3622
80-24719-247300-4130-4138
90-27809-278200-4646-4654
100-30899-309100-5162-5170

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%1.029.00.03.3%1.029.00.03.3%
Book Value Change Per Share0.04.00.00.0%1.011.00.08.3%4.016.00.020.0%5.022.03.016.7%5.022.03.016.7%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.030.00.0%0.00.030.00.0%
Total Gains per Share0.04.00.00.0%1.011.00.08.3%4.016.00.020.0%5.022.03.016.7%5.022.03.016.7%
3rd party ad coffee SUPPORTERis ad-free.

Fundamentals of BioXcel Therapeutics Inc

About BioXcel Therapeutics Inc

BioXcel Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI, a sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the acute treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally innate immunity activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors; BXCL503, a drug candidate to target apathy in dementia; and BXCL504, a drug candidate to target aggression in dementia. BioXcel Therapeutics, Inc. was incorporated in 2017 and is headquartered in New Haven, Connecticut.

Fundamental data was last updated by Penke on 2024-06-17 16:26:04.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is unable to pay all its debts by selling its assets.
The company is unable to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is overpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

1.1. Profitability of BioXcel Therapeutics Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit BioXcel Therapeutics Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare BioXcel Therapeutics Inc to the Biotechnology industry mean.
  • A Net Profit Margin of -4,603.3% means that $-46.03 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of BioXcel Therapeutics Inc:

  • The MRQ is -4,603.3%. The company is making a huge loss. -2
  • The TTM is -9,259.4%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-4,603.3%TTM-9,259.4%+4,656.2%
TTM-9,259.4%YOY-20,436.3%+11,176.9%
TTM-9,259.4%5Y-17,648,036,071.9%+17,648,026,812.4%
5Y-17,648,036,071.9%10Y-11,765,357,381.2%-5,882,678,690.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-4,603.3%-168.0%-4,435.3%
TTM-9,259.4%-209.9%-9,049.5%
YOY-20,436.3%-242.3%-20,194.0%
5Y-17,648,036,071.9%-401.7%-17,648,035,670.2%
10Y-11,765,357,381.2%-532.2%-11,765,356,849.0%
1.1.2. Return on Assets

Shows how efficient BioXcel Therapeutics Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare BioXcel Therapeutics Inc to the Biotechnology industry mean.
  • -32.5% Return on Assets means that BioXcel Therapeutics Inc generated $-0.33 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of BioXcel Therapeutics Inc:

  • The MRQ is -32.5%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -37.8%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-32.5%TTM-37.8%+5.3%
TTM-37.8%YOY-22.6%-15.2%
TTM-37.8%5Y-21.8%-16.0%
5Y-21.8%10Y-1,989.8%+1,968.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-32.5%-11.9%-20.6%
TTM-37.8%-11.9%-25.9%
YOY-22.6%-11.3%-11.3%
5Y-21.8%-13.5%-8.3%
10Y-1,989.8%-14.9%-1,974.9%
1.1.3. Return on Equity

Shows how efficient BioXcel Therapeutics Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare BioXcel Therapeutics Inc to the Biotechnology industry mean.
  • 0.0% Return on Equity means BioXcel Therapeutics Inc generated $0.00 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of BioXcel Therapeutics Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-228.2%+228.2%
TTM-228.2%YOY-57.7%-170.4%
TTM-228.2%5Y-69.0%-159.2%
5Y-69.0%10Y-48.2%-20.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--14.2%+14.2%
TTM-228.2%-15.7%-212.5%
YOY-57.7%-14.3%-43.4%
5Y-69.0%-19.2%-49.8%
10Y-48.2%-19.7%-28.5%
3rd party ad coffee SUPPORTERis ad-free.

1.2. Operating Efficiency of BioXcel Therapeutics Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient BioXcel Therapeutics Inc is operating .

  • Measures how much profit BioXcel Therapeutics Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare BioXcel Therapeutics Inc to the Biotechnology industry mean.
  • An Operating Margin of -4,111.5% means the company generated $-41.12  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of BioXcel Therapeutics Inc:

  • The MRQ is -4,111.5%. The company is operating very inefficient. -2
  • The TTM is -8,246.5%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-4,111.5%TTM-8,246.5%+4,135.0%
TTM-8,246.5%YOY-18,899.9%+10,653.4%
TTM-8,246.5%5Y-17,669,535,549.6%+17,669,527,303.1%
5Y-17,669,535,549.6%10Y-11,779,690,366.4%-5,889,845,183.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-4,111.5%-354.6%-3,756.9%
TTM-8,246.5%-225.9%-8,020.6%
YOY-18,899.9%-252.2%-18,647.7%
5Y-17,669,535,549.6%-428.3%-17,669,535,121.3%
10Y-11,779,690,366.4%-531.1%-11,779,689,835.3%
1.2.2. Operating Ratio

Measures how efficient BioXcel Therapeutics Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 42.12 means that the operating costs are $42.12 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of BioXcel Therapeutics Inc:

  • The MRQ is 42.115. The company is inefficient in keeping operating costs low. -1
  • The TTM is 85.425. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ42.115TTM85.425-43.310
TTM85.425YOY189.594-104.169
TTM85.4255Y176,582,856.326-176,582,770.901
5Y176,582,856.32610Y117,721,904.217+58,860,952.109
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ42.1153.004+39.111
TTM85.4253.332+82.093
YOY189.5943.502+186.092
5Y176,582,856.3265.271+176,582,851.055
10Y117,721,904.2176.915+117,721,897.302
3rd party ad coffee SUPPORTERis ad-free.

1.3. Liquidity of BioXcel Therapeutics Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if BioXcel Therapeutics Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 2.57 means the company has $2.57 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of BioXcel Therapeutics Inc:

  • The MRQ is 2.570. The company is able to pay all its short-term debts. +1
  • The TTM is 2.925. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ2.570TTM2.925-0.355
TTM2.925YOY8.729-5.804
TTM2.9255Y9.310-6.385
5Y9.31010Y9.164+0.147
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.5703.767-1.197
TTM2.9254.000-1.075
YOY8.7294.905+3.824
5Y9.3105.883+3.427
10Y9.1646.286+2.878
1.3.2. Quick Ratio

Measures if BioXcel Therapeutics Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare BioXcel Therapeutics Inc to the Biotechnology industry mean.
  • A Quick Ratio of 2.37 means the company can pay off $2.37 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of BioXcel Therapeutics Inc:

  • The MRQ is 2.367. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 2.687. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ2.367TTM2.687-0.320
TTM2.687YOY8.482-5.796
TTM2.6875Y9.093-6.406
5Y9.09310Y8.977+0.116
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.3673.054-0.687
TTM2.6873.506-0.819
YOY8.4824.756+3.726
5Y9.0935.757+3.336
10Y8.9776.338+2.639
3rd party ad coffee SUPPORTERis ad-free.

1.4. Solvency of BioXcel Therapeutics Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of BioXcel Therapeutics Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare BioXcel Therapeutics Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 1.88 means that BioXcel Therapeutics Inc assets are financed with 187.9% credit (debt) and the remaining percentage (100% - 187.9%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of BioXcel Therapeutics Inc:

  • The MRQ is 1.879. The company is unable to pay all its debts by selling its assets. -2
  • The TTM is 1.502. The company is unable to pay all its debts by selling its assets. -2
Trends
Current periodCompared to+/- 
MRQ1.879TTM1.502+0.377
TTM1.502YOY0.538+0.964
TTM1.5025Y0.488+1.014
5Y0.48810Y6.703-6.215
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.8790.330+1.549
TTM1.5020.342+1.160
YOY0.5380.287+0.251
5Y0.4880.368+0.120
10Y6.7030.382+6.321
1.4.2. Debt to Equity Ratio

Measures if BioXcel Therapeutics Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare BioXcel Therapeutics Inc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 0.0% means that company has $0.00 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of BioXcel Therapeutics Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM5.723-5.723
TTM5.723YOY1.380+4.343
TTM5.7235Y1.520+4.203
5Y1.52010Y1.031+0.489
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-0.365-0.365
TTM5.7230.415+5.308
YOY1.3800.370+1.010
5Y1.5200.443+1.077
10Y1.0310.476+0.555
3rd party ad coffee SUPPORTERis ad-free.

2. Market Valuation of BioXcel Therapeutics Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings BioXcel Therapeutics Inc generates.

  • Above 15 is considered overpriced but always compare BioXcel Therapeutics Inc to the Biotechnology industry mean.
  • A PE ratio of -0.99 means the investor is paying $-0.99 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of BioXcel Therapeutics Inc:

  • The EOD is -0.378. Based on the earnings, the company is expensive. -2
  • The MRQ is -0.988. Based on the earnings, the company is expensive. -2
  • The TTM is -0.967. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.378MRQ-0.988+0.609
MRQ-0.988TTM-0.967-0.020
TTM-0.967YOY-3.233+2.266
TTM-0.9675Y-8.825+7.857
5Y-8.82510Y-8.672-0.153
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.378-2.341+1.963
MRQ-0.988-2.997+2.009
TTM-0.967-2.882+1.915
YOY-3.233-3.553+0.320
5Y-8.825-6.262-2.563
10Y-8.672-6.288-2.384
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of BioXcel Therapeutics Inc:

  • The EOD is -0.572. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -1.494. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -1.198. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.572MRQ-1.494+0.922
MRQ-1.494TTM-1.198-0.297
TTM-1.198YOY-3.964+2.766
TTM-1.1985Y-10.909+9.711
5Y-10.90910Y-12.516+1.606
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.572-2.932+2.360
MRQ-1.494-3.739+2.245
TTM-1.198-3.776+2.578
YOY-3.964-4.917+0.953
5Y-10.909-7.942-2.967
10Y-12.516-8.503-4.013
3rd party ad coffee SUPPORTERis ad-free.
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of BioXcel Therapeutics Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of -1.46 means the investor is paying $-1.46 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of BioXcel Therapeutics Inc:

  • The EOD is -0.560. Based on the equity, the company is expensive. -2
  • The MRQ is -1.463. Based on the equity, the company is expensive. -2
  • The TTM is 9.216. Based on the equity, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD-0.560MRQ-1.463+0.902
MRQ-1.463TTM9.216-10.679
TTM9.216YOY7.556+1.661
TTM9.2165Y10.048-0.831
5Y10.04810Y7.891+2.157
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.5601.843-2.403
MRQ-1.4632.249-3.712
TTM9.2162.301+6.915
YOY7.5562.412+5.144
5Y10.0483.782+6.266
10Y7.8914.212+3.679
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of BioXcel Therapeutics Inc.

3.1. Institutions holding BioXcel Therapeutics Inc

Institutions are holding 34.177% of the shares of BioXcel Therapeutics Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-03-31FMR Inc6.64550.00052494116-24448-0.9707
2024-03-31BlackRock Inc3.53860.00011328061-46148-3.3582
2024-03-31Vanguard Group Inc2.92930.0001109937599120.9098
2024-03-31Ameriprise Financial Inc1.54320.0005579164381007.0417
2024-03-31State Street Corporation1.23870.0001464908245765.5812
2024-03-31Geode Capital Management, LLC1.22010.000145792076931.7087
2024-03-31Armistice Capital, LLC0.98840.01393709733709730
2024-03-31Beacon Pointe Advisors, LLC0.8040.009530173500
2024-03-31Morgan Stanley - Brokerage Accounts0.59230.00012222993054515.9293
2024-03-31Northern Trust Corp0.56380.0001211602-13787-6.117
2024-03-31Charles Schwab Investment Management Inc0.50880.000119097034601.8452
2024-03-31UBS Group AG0.39210.000114715798837204.5468
2024-03-31Wells Fargo & Co0.3280.00011230864525758.1493
2024-03-31Bank of New York Mellon Corp0.32790.0001123077-3429-2.7105
2024-03-31Castleview Partners, LLC0.25920.153297279972790
2024-03-31Susquehanna International Group, LLP0.2403090190901900
2024-03-31Pennant Investors LP0.22350.05868390000
2024-03-31Tocqueville Asset Management L.P.0.12860.002248250-2000-3.9801
2024-03-31Federated Hermes Inc0.12760.000347907479070
2024-03-31Bank of America Corp0.1262047368-56961-54.5975
Total 22.72610.23978529337+717956+8.4%

3.2. Funds holding BioXcel Therapeutics Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-04-30Fidelity Growth Compy Commingled Pl O2.74950.0033101827019130.1882
2024-04-30Fidelity Growth Company Fund1.84680.003683960-6607-0.9568
2024-04-30Vanguard Total Stock Mkt Idx Inv1.72880.000164024500
2024-05-30iShares Russell 2000 ETF1.27750.001447310536080.7685
2024-03-31Columbia Small Cap Value I0.99750.07369426185005.2718
2024-04-30Fidelity Growth Company K60.86970.004532209230940.9699
2024-04-30Vanguard Institutional Extnd Mkt Idx Tr0.7920.000829332200
2024-04-30Fidelity Select Biotechnology0.74130.01627452700
2024-03-31Fidelity Small Cap Index0.55860.002220687032031.5727
2024-04-30Fidelity Series Growth Company0.51240.0031189760-1000-0.5242
2024-05-30iShares Russell 2000 Growth ETF0.43570.002616135000
2024-05-31State St Russell Sm/Mid Cp® Indx NL Cl C0.33150.000512276100
2024-04-30Fidelity Extended Market Index0.30420.0008112675-1021-0.898
2024-05-31Schwab US Small-Cap ETF™0.26660.00119873300
2024-04-30Vanguard Russell 2000 ETF0.20720.002767382720.3557
2024-05-31BSO Bio Santé C0.1890.05267000000
2024-05-31State St Russell Sm Cap® Indx SL Cl I0.18640.00136902500
2023-12-31NT R2000 Growth Index Fund - NL0.15550.00465760300
2024-03-31NT R2000 Index Fund - NL0.14930.002155291430.0778
2024-04-30Schwab Small Cap Index0.13480.00224990800
Total 14.43430.17425345661+22005+0.4%

3.3. Insider Transactions

Insiders are holding 21.767% of the shares of BioXcel Therapeutics Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-06-04Vimal MehtaSELL1260141.63
2024-04-04Richard I SteinhartSELL10692.63
2024-04-04Vimal MehtaSELL52682.62
2024-04-04Vincent O'neillSELL1652.62
2023-06-15Vimal MehtaSELL3000021.54
3rd party ad coffee SUPPORTERis ad-free.

4. Summary

4.1. Key Performance Indicators

The key performance indicators of BioXcel Therapeutics Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.422-0.835+98%-0.939+122%-0.140-67%-0.064-85%
Book Value Per Share---1.928-1.090-43%2.805-169%2.682-172%1.980-197%
Current Ratio--2.5702.925-12%8.729-71%9.310-72%9.164-72%
Debt To Asset Ratio--1.8791.502+25%0.538+249%0.488+285%6.703-72%
Debt To Equity Ratio---5.723-100%1.380-100%1.520-100%1.031-100%
Dividend Per Share----0%-0%-0%-0%
Eps---0.714-1.019+43%-1.246+75%-0.781+9%-0.550-23%
Free Cash Flow Per Share---0.472-0.802+70%-1.034+119%-0.639+35%-0.447-5%
Free Cash Flow To Equity Per Share--0.238-0.610+357%-0.233+198%0.226+5%0.183+30%
Gross Profit Margin--1.0021.041-4%1.179-15%1.063-6%1.042-4%
Intrinsic Value_10Y_max---25.047--------
Intrinsic Value_10Y_min---21.989--------
Intrinsic Value_1Y_max---3.185--------
Intrinsic Value_1Y_min---3.129--------
Intrinsic Value_3Y_max---9.054--------
Intrinsic Value_3Y_min---8.655--------
Intrinsic Value_5Y_max---14.304--------
Intrinsic Value_5Y_min---13.321--------
Market Cap40533264.000-161%105836856.000140365192.000-25%611376732.000-83%790886548.400-87%578362138.267-82%
Net Profit Margin---46.033-92.594+101%-204.363+344%-176480360.719+383380774%-117653573.812+255587149%
Operating Margin---41.115-82.465+101%-188.999+360%-176695355.496+429757503%-117796903.664+286504969%
Operating Ratio--42.11585.425-51%189.594-78%176582856.326-100%117721904.217-100%
Pb Ratio-0.560+62%-1.4639.216-116%7.556-119%10.048-115%7.891-119%
Pe Ratio-0.378+62%-0.988-0.967-2%-3.233+227%-8.825+794%-8.672+778%
Price Per Share1.080-161%2.8203.740-25%16.290-83%21.073-87%15.410-82%
Price To Free Cash Flow Ratio-0.572+62%-1.494-1.198-20%-3.964+165%-10.909+630%-12.516+738%
Price To Total Gains Ratio-2.556+62%-6.675-5.246-21%-18.517+177%-28.693+330%-34.698+420%
Quick Ratio--2.3672.687-12%8.482-72%9.093-74%8.977-74%
Return On Assets---0.325-0.378+16%-0.226-30%-0.218-33%-19.898+6014%
Return On Equity----2.2820%-0.5770%-0.6900%-0.4820%
Total Gains Per Share---0.422-0.835+98%-0.939+122%-0.140-67%-0.064-85%
Usd Book Value---72363000.000-40903750.000-43%105257000.000-169%100644500.000-172%74320633.333-197%
Usd Book Value Change Per Share---0.422-0.835+98%-0.939+122%-0.140-67%-0.064-85%
Usd Book Value Per Share---1.928-1.090-43%2.805-169%2.682-172%1.980-197%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.714-1.019+43%-1.246+75%-0.781+9%-0.550-23%
Usd Free Cash Flow---17706000.000-30094750.000+70%-38825000.035+119%-23967800.007+35%-16761633.338-5%
Usd Free Cash Flow Per Share---0.472-0.802+70%-1.034+119%-0.639+35%-0.447-5%
Usd Free Cash Flow To Equity Per Share--0.238-0.610+357%-0.233+198%0.226+5%0.183+30%
Usd Market Cap40533264.000-161%105836856.000140365192.000-25%611376732.000-83%790886548.400-87%578362138.267-82%
Usd Price Per Share1.080-161%2.8203.740-25%16.290-83%21.073-87%15.410-82%
Usd Profit---26791000.000-38262000.000+43%-48196000.000+80%-29608000.000+11%-20843100.000-22%
Usd Revenue--582000.000439000.000+33%145250.000+301%118881.052+390%79254.034+634%
Usd Total Gains Per Share---0.422-0.835+98%-0.939+122%-0.140-67%-0.064-85%
 EOD+2 -6MRQTTM+22 -11YOY+20 -135Y+16 -1710Y+12 -21

4.2. Fundamental Score

Let's check the fundamental score of BioXcel Therapeutics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-0.378
Price to Book Ratio (EOD)Between0-1-0.560
Net Profit Margin (MRQ)Greater than0-46.033
Operating Margin (MRQ)Greater than0-41.115
Quick Ratio (MRQ)Greater than12.367
Current Ratio (MRQ)Greater than12.570
Debt to Asset Ratio (MRQ)Less than11.879
Debt to Equity Ratio (MRQ)Less than10.000
Return on Equity (MRQ)Greater than0.150.000
Return on Assets (MRQ)Greater than0.05-0.325
Total3/10 (30.0%)

4.3. Technical Score

Let's check the technical score of BioXcel Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5025.761
Ma 20Greater thanMa 501.304
Ma 50Greater thanMa 1001.841
Ma 100Greater thanMa 2002.355
OpenGreater thanClose1.120
Total1/5 (20.0%)



Latest Balance Sheet

Balance Sheet of 2024-03-31. Currency in USD. All numbers in thousands.

Summary
Total Assets82,323
Total Liabilities154,686
Total Stockholder Equity-72,363
 As reported
Total Liabilities 154,686
Total Stockholder Equity+ -72,363
Total Assets = 82,323

Assets

Total Assets82,323
Total Current Assets80,917
Long-term Assets1,406
Total Current Assets
Cash And Cash Equivalents 74,141
Net Receivables 378
Inventory 2,439
Other Current Assets 3,959
Total Current Assets  (as reported)80,917
Total Current Assets  (calculated)80,917
+/-0
Long-term Assets
Property Plant Equipment 1,319
Long-term Assets Other 87
Long-term Assets  (as reported)1,406
Long-term Assets  (calculated)1,406
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities31,481
Long-term Liabilities123,205
Total Stockholder Equity-72,363
Total Current Liabilities
Short-term Debt 353
Accounts payable 17,220
Other Current Liabilities 13,823
Total Current Liabilities  (as reported)31,481
Total Current Liabilities  (calculated)31,396
+/- 85
Long-term Liabilities
Long term Debt 101,633
Capital Lease Obligations 350
Long-term Liabilities  (as reported)123,205
Long-term Liabilities  (calculated)101,983
+/- 21,222
Total Stockholder Equity
Common Stock34
Retained Earnings -617,389
Other Stockholders Equity 544,992
Total Stockholder Equity (as reported)-72,363
Total Stockholder Equity (calculated)-72,363
+/-0
Other
Capital Stock34
Cash and Short Term Investments 74,141
Common Stock Shares Outstanding 30,868
Current Deferred Revenue85
Liabilities and Stockholders Equity 82,323
Net Debt 28,195
Net Invested Capital 29,270
Net Working Capital 49,436
Property Plant and Equipment Gross 2,590
Short Long Term Debt Total 102,336



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-31
> Total Assets 
7
0
0
0
1,355
56,321
51,210
47,866
43,549
40,328
34,278
43,697
36,392
85,812
70,462
238,749
219,936
200,389
281,107
261,332
239,439
211,045
248,235
244,818
205,853
180,103
140,097
100,449
73,702
82,323
82,32373,702100,449140,097180,103205,853244,818248,235211,045239,439261,332281,107200,389219,936238,74970,46285,81236,39243,69734,27840,32843,54947,86651,21056,3211,3550007
   > Total Current Assets 
2
0
0
0
890
56,317
51,088
47,638
43,171
38,079
31,511
41,361
34,107
83,598
68,313
236,133
217,065
196,783
276,658
256,929
232,968
207,562
244,924
241,661
202,868
177,268
138,235
98,738
72,143
80,917
80,91772,14398,738138,235177,268202,868241,661244,924207,562232,968256,929276,658196,783217,065236,13368,31383,59834,10741,36131,51138,07943,17147,63851,08856,3178900002
       Cash And Cash Equivalents 
0
0
0
0
887
55,465
50,349
47,122
42,565
36,296
29,965
40,252
32,426
80,079
65,495
233,428
213,119
194,015
273,057
252,912
232,968
200,435
233,452
232,314
193,725
165,521
127,545
89,961
65,221
74,141
74,14165,22189,961127,545165,521193,725232,314233,452200,435232,968252,912273,057194,015213,119233,42865,49580,07932,42640,25229,96536,29642,56547,12250,34955,4658870000
       Net Receivables 
0
0
0
0
0
44
70
49
115
115
46
0
0
0
0
0
0
0
0
0
0
4,967
8,384
5,509
248
283
431
735
71
378
378717354312832485,5098,3844,96700000000004611511549704400000
       Other Current Assets 
2
0
0
0
3
808
669
467
491
1,783
1,500
1,109
1,681
3,519
2,818
2,705
3,946
2,768
3,601
4,017
956
1,478
1,693
2,430
3,843
5,006
4,636
2,171
4,860
3,959
3,9594,8602,1714,6365,0063,8432,4301,6931,4789564,0173,6012,7683,9462,7052,8183,5191,6811,1091,5001,78349146766980830002
   > Long-term Assets 
0
0
0
0
465
4
122
228
378
2,249
2,767
2,336
2,285
2,214
2,149
2,616
2,871
3,606
4,449
4,403
6,471
3,483
3,311
3,157
2,985
2,835
1,862
1,711
1,559
1,406
1,4061,5591,7111,8622,8352,9853,1573,3113,4836,4714,4034,4493,6062,8712,6162,1492,2142,2852,3362,7672,24937822812244650000
       Property Plant Equipment 
5
0
0
0
4
4
122
177
327
2,198
2,338
2,285
2,234
2,163
2,098
2,530
2,784
2,973
2,819
2,648
2,541
2,518
2,386
2,232
2,060
1,910
1,775
1,624
1,472
1,319
1,3191,4721,6241,7751,9102,0602,2322,3862,5182,5412,6482,8192,9732,7842,5302,0982,1632,2342,2852,3382,198327177122440005
       Other Assets 
0
0
0
0
461
0
0
51
51
51
429
51
51
51
51
86
1,598
633
1,630
1,755
86
965
248,235
925
925
0
87
0
0
0
000870925925248,235965861,7551,6306331,5988651515151429515151004610000
> Total Liabilities 
331
0
0
0
2,337
4,215
1,389
2,043
4,660
7,960
9,121
9,277
9,497
13,226
17,068
17,811
13,240
13,652
13,696
15,776
17,772
17,025
83,973
117,832
129,078
127,098
134,233
141,057
130,210
154,686
154,686130,210141,057134,233127,098129,078117,83283,97317,02517,77215,77613,69613,65213,24017,81117,06813,2269,4979,2779,1217,9604,6602,0431,3894,2152,337000331
   > Total Current Liabilities 
331
0
0
0
2,337
4,215
1,389
2,043
4,660
6,807
8,009
8,206
8,468
12,265
16,161
16,344
11,842
12,324
12,441
14,596
16,667
15,997
19,995
23,378
32,898
28,759
34,744
39,408
27,267
31,481
31,48127,26739,40834,74428,75932,89823,37819,99515,99716,66714,59612,44112,32411,84216,34416,16112,2658,4688,2068,0096,8074,6602,0431,3894,2152,337000331
       Short-term Debt 
0
0
0
0
371
0
0
0
0
156
0
0
0
0
0
0
237
371
0
287
293
299
306
312
319
325
332
339
346
353
353346339332325319312306299293287037123700000015600003710000
       Short Long Term Debt 
0
0
0
0
878
0
0
0
0
156
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000015600008780000
       Accounts payable 
279
0
0
0
444
3,935
889
1,213
1,604
2,128
3,979
4,238
4,953
6,733
10,434
8,557
3,979
5,310
2,497
3,439
4,678
5,065
6,021
5,872
10,228
7,742
11,203
10,669
13,654
17,220
17,22013,65410,66911,2037,74210,2285,8726,0215,0654,6783,4392,4975,3103,9798,55710,4346,7334,9534,2383,9792,1281,6041,2138893,935444000279
       Other Current Liabilities 
52
0
0
0
1,522
280
500
830
3,056
4,679
4,030
3,968
3,515
5,532
5,727
7,787
237
7,014
9,944
10,671
11,989
10,633
13,668
17,194
22,351
20,692
121
28,739
13,151
13,823
13,82313,15128,73912120,69222,35117,19413,66810,63311,98910,6719,9447,0142377,7875,7275,5323,5153,9684,0304,6793,0568305002801,52200052
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
1,153
1,112
1,071
1,029
961
907
1,467
1,398
1,328
1,255
1,180
1,105
1,028
63,978
94,454
96,180
98,339
99,489
101,649
102,943
123,205
123,205102,943101,64999,48998,33996,18094,45463,9781,0281,1051,1801,2551,3281,3981,4679079611,0291,0711,1121,153000000000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
61,075
91,695
93,051
95,062
96,846
0
0
0
00096,84695,06293,05191,69561,0750000000000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,954
1,891
2,343
0
2,026
0
0
0
0002,02602,3431,8911,9540000000000000000000000
       Deferred Long Term Liability 
0
0
0
0
461
0
0
0
0
0
378
0
0
0
0
0
0
0
0
0
0
0
1,954
1,891
2,343
2,574
2,026
0
0
0
0002,0262,5742,3431,8911,95400000000000378000004610000
> Total Stockholder Equity
-324
-324
0
0
-982
52,106
49,821
45,823
38,889
32,368
25,157
34,420
26,895
72,586
53,394
220,938
206,696
186,737
267,411
245,556
221,667
194,020
164,262
126,986
76,775
53,005
5,864
-40,608
-56,508
-72,363
-72,363-56,508-40,6085,86453,00576,775126,986164,262194,020221,667245,556267,411186,737206,696220,93853,39472,58626,89534,42025,15732,36838,88945,82349,82152,106-98200-324-324
   Common Stock
-324
0
0
0
10
16
16
16
16
16
16
18
18
20
20
24
24
25
28
28
28
28
28
28
28
29
29
29
30
34
3430292929282828282828282524242020181816161616161610000-324
   Retained Earnings Total Equity000-517,856-464,341-411,545-356,737-314,930-277,260-245,788-219,663-192,852-165,233-138,857-117,771-93,018-71,599-56,688-48,413-39,395-30,924-23,720-16,645-11,758-8,73200000
   Accumulated Other Comprehensive Income 00000000000000-317-269-221-174-127-78-40-18-10-3-1-10000
   Capital Surplus 
0
0
0
0
0
60,822
61,563
62,452
62,593
63,276
64,536
82,815
83,565
144,165
146,392
338,685
345,529
351,945
460,235
465,191
467,427
471,252
479,164
483,695
488,292
517,317
523,691
0
0
0
000523,691517,317488,292483,695479,164471,252467,427465,191460,235351,945345,529338,685146,392144,16583,56582,81564,53663,27662,59362,45261,56360,82200000
   Treasury Stock000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
0
3,459
60,823
61,566
62,462
62,611
63,316
64,614
82,942
83,739
144,386
146,661
339,002
345,529
351,945
460,235
465,191
467,427
471,252
479,164
483,695
488,292
517,317
523,691
527,705
534,060
544,992
544,992534,060527,705523,691517,317488,292483,695479,164471,252467,427465,191460,235351,945345,529339,002146,661144,38683,73982,94264,61463,31662,61162,46261,56660,8233,4590000



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue1,380
Cost of Revenue-1,578
Gross Profit-198-198
 
Operating Income (+$)
Gross Profit-198
Operating Expense-166,135
Operating Income-166,333-166,333
 
Operating Expense (+$)
Research Development82,933
Selling General Administrative70,928
Selling And Marketing Expenses12,485
Operating Expense166,135166,346
 
Net Interest Income (+$)
Interest Income6,189
Interest Expense-13,314
Other Finance Cost-515
Net Interest Income-6,610
 
Pretax Income (+$)
Operating Income-166,333
Net Interest Income-6,610
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-179,053-153,613
EBIT - interestExpense = -179,647
-179,053
-165,739
Interest Expense13,314
Earnings Before Interest and Taxes (EBIT)-166,333-165,739
Earnings Before Interest and Taxes (EBITDA)-166,015
 
After tax Income (+$)
Income Before Tax-179,053
Tax Provision-0
Net Income From Continuing Ops-211,605-179,053
Net Income-179,053
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses167,713
Total Other Income/Expenses Net-12,7206,610
 

Technical Analysis of BioXcel Therapeutics Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of BioXcel Therapeutics Inc. The general trend of BioXcel Therapeutics Inc is BEARISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine BioXcel Therapeutics Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-100.0%) Bearish trend (100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of BioXcel Therapeutics Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is -1/(-1 +1).

  • Around resistance: The price is trading arround resistance levels. This can be considered as a potential exit level. -1

The bullish price targets are: 1.11 < 1.57 < 1.91.

The bearish price targets are: .

Tweet this
BioXcel Therapeutics Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of BioXcel Therapeutics Inc. The current mas is .

The long score for the Moving Averages is 0/14.
The longshort score for the Moving Averages is -14/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

BioXcel Therapeutics Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of BioXcel Therapeutics Inc. The current macd is -0.19595939.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the BioXcel Therapeutics Inc price going up in the near term. +2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for BioXcel Therapeutics Inc. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the BioXcel Therapeutics Inc price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
BioXcel Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) ChartBioXcel Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of BioXcel Therapeutics Inc. The current adx is 31.46.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -3/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell BioXcel Therapeutics Inc shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX > 25 && ADX trending down: The ADX is above 25 and indicates a strong bearish trend. The ADX is declining, the bearish trend is weakening. Could be a potential reversal to the upside. -2
BioXcel Therapeutics Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of BioXcel Therapeutics Inc. The current sar is 1.543936.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
BioXcel Therapeutics Inc Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of BioXcel Therapeutics Inc. The current rsi is 25.76. The current phase is Oversold in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is 0/(-13 +13).

  • Oversold in bear market: Short-term excessive selling, potential for relief rally. Be cautious, consider taking short-term long positions. +1
  • Trending down: The RSI is trending down. -1
BioXcel Therapeutics Inc Daily Relative Strength Index (RSI) ChartBioXcel Therapeutics Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of BioXcel Therapeutics Inc. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 1/6.
The longshort score for the Stochastic Oscillator is -4/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the BioXcel Therapeutics Inc price going down in the near term. -2
  • Trending up: The STOCH %K is trending up. +1
BioXcel Therapeutics Inc Daily Stochastic Oscillator ChartBioXcel Therapeutics Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of BioXcel Therapeutics Inc. The current cci is -130.05813026.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
BioXcel Therapeutics Inc Daily Commodity Channel Index (CCI) ChartBioXcel Therapeutics Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of BioXcel Therapeutics Inc. The current cmo is -49.31895848.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
BioXcel Therapeutics Inc Daily Chande Momentum Oscillator (CMO) ChartBioXcel Therapeutics Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of BioXcel Therapeutics Inc. The current willr is -96.07843137.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
BioXcel Therapeutics Inc Daily Williams %R ChartBioXcel Therapeutics Inc Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of BioXcel Therapeutics Inc.

BioXcel Therapeutics Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of BioXcel Therapeutics Inc. The current atr is 0.13221955.

BioXcel Therapeutics Inc Daily Average True Range (ATR) ChartBioXcel Therapeutics Inc Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of BioXcel Therapeutics Inc. The current obv is 85,564,372.

BioXcel Therapeutics Inc Daily On-Balance Volume (OBV) ChartBioXcel Therapeutics Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of BioXcel Therapeutics Inc. The current mfi is 57.69.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
BioXcel Therapeutics Inc Daily Money Flow Index (MFI) ChartBioXcel Therapeutics Inc Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for BioXcel Therapeutics Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-02-13STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-14DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-15ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-16MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-02-20STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-21CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-22CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-23DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-26MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-02-27MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-04MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-06WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-08DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-11DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-12STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-13CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-15STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-27MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-03-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-02MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-04STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-08STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-09CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-10STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-11MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-12DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-04-15STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-17WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-18MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-19MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-23CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-04-24STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-25WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-29MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-04-30CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-05-02STOCH SHORT EXITThe %K line crosses above the %D line.
2024-05-06STOCH LONG EXITThe %K line crosses below the %D line.
2024-05-07DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-05-08SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-05-09RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-05-10STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-05-13STOCH SHORT EXITThe %K line crosses above the %D line.
2024-05-15STOCH LONG EXITThe %K line crosses below the %D line.
2024-05-20STOCH SHORT EXITThe %K line crosses above the %D line.
2024-05-21STOCH LONG EXITThe %K line crosses below the %D line.
2024-05-22CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-05-24RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-05-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-05-31RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-06-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-06-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-06-06BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-06-07STOCH LONG EXITThe %K line crosses below the %D line.
2024-06-10STOCH SHORT EXITThe %K line crosses above the %D line.
2024-06-13STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-06-17STOCH SHORT EXITThe %K line crosses above the %D line.
2024-06-18STOCH LONG EXITThe %K line crosses below the %D line.
2024-06-21STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-06-25SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-06-26MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-06-28DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-07-01DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-07-02CCI SHORT ENTRY LONG CLOSE-100 crossover to downside

6.3. Candlestick Patterns

BioXcel Therapeutics Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of BioXcel Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5025.761
Ma 20Greater thanMa 501.304
Ma 50Greater thanMa 1001.841
Ma 100Greater thanMa 2002.355
OpenGreater thanClose1.120
Total1/5 (20.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of BioXcel Therapeutics Inc with someone you think should read this too:
  • Are you bullish or bearish on BioXcel Therapeutics Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about BioXcel Therapeutics Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about BioXcel Therapeutics Inc

I send you an email if I find something interesting about BioXcel Therapeutics Inc.


Stay informed about BioXcel Therapeutics Inc.

Receive notifications about BioXcel Therapeutics Inc in your mailbox!